Citicoline / Piracetam Tablet Suppliers & Bulk Manufacturers
Available Forms: Tablets
Available Strengths: 500mg + 800mg
Reference Brands: Nootropil C (India/LATAM/EU), Sitcol‑P (India/EU)
Category:
Antipsychotropic Drugs
Citicoline + Piracetam is a combination of two medicines: Citicoline and Piracetam. Citicoline is a nerve protecting medicine. It works on the brain by nourishing the nerve cells, protects them from damage and improves their survival. Piracetam is a GABA (gamma amino butyric acid) analogue.
Citicoline / Piracetam Tablet is available in Tablets
and strengths such as 500mg + 800mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Citicoline / Piracetam Tablet is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Citicoline / Piracetam Tablet can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Perinatal hypoxic-ischemic brain injury is a leading cause of neonatal mortality and long-term neurodevelopmental complications. Research has shown that neuroprotective agents can play a critical role in mitigating brain damage in newborns exposed to oxygen deprivation at birth. Citicoline and Piracetam, both well-known nootropic agents, have been studied for their potential to enhance neuronal repair, improve cognitive outcomes, and protect against oxidative stress in such conditions.
In preclinical studies using neonatal rabbit models, Citicoline and Piracetam were evaluated both individually and in combination to determine their efficacy in reducing hypoxic-ischemic brain injury. Citicoline supports membrane stabilization, enhances neurotransmitter synthesis, and promotes neuronal recovery, while Piracetam improves cerebral blood flow, oxygen utilization, and synaptic function. The combination of these agents demonstrated synergistic neuroprotective effects, suggesting a promising therapeutic approach for minimizing brain damage, improving functional outcomes, and supporting neurodevelopment in neonates affected by perinatal hypoxia-ischemia.
This investigation highlights the potential of Citicoline and Piracetam as complementary neuroprotective therapies in neonatal care, offering hope for better management and long-term neurological outcomes in affected newborns.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing